Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors

Publish date:: October 16, 2019

Key clinical point: Routine pneumocystis jiroveci pneumonia prophylaxis may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase inhibitor therapy.

Major finding: Pneumocystis jiroveci pneumonia incidence in patients on prophylaxis was 0% versus 3.4% for patients not receiving prophylaxis. The number needed to treat to prevent 1 case was 42 patients.

Study details: A retrospective chart review involving 212 patients.

Disclosures: Dr. Ryan reported having no financial disclosures.

Citation:

Ryan C et al. iwCLL 2019, Abstract 1941.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

All Specialties